# NCT06445062 (NCT06445062)

> Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A report exists for this trial.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06445062
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions: RMC-6236; mFOLFOX6 regimen; bevacizumab; mFOLFIRINOX regimen; cetuximab; gemcitabine; nab-paclitaxel; RMC-9805; FOLFIRI regimen
- Enrollment: 1130
- Primary outcome: Adverse events (Subprotocols A-F)
- Primary outcome: Dose limiting toxicities (Subprotocols A-F)
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)

## Indexed commentary on NCT06445062 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

None in our index yet.